These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution. Do C; DeAguero J; Brearley A; Trejo X; Howard T; Escobar GP; Wagner B Kidney360; 2020 Jun; 1(6):561-568. PubMed ID: 34423308 [TBL] [Abstract][Full Text] [Related]
5. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review. Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045 [TBL] [Abstract][Full Text] [Related]
6. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families. Noda SM; Oztek MA; Stanescu AL; Maloney E; Shaw DWW; Iyer RS Pediatr Radiol; 2022 Feb; 52(2):345-353. PubMed ID: 33978802 [TBL] [Abstract][Full Text] [Related]
7. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? Weinreb JC; Abu-Alfa AK J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035 [TBL] [Abstract][Full Text] [Related]
9. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792 [TBL] [Abstract][Full Text] [Related]
10. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421 [No Abstract] [Full Text] [Related]
11. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Penfield JG Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004 [TBL] [Abstract][Full Text] [Related]
12. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging. Holowka S; Shroff M; Chavhan GB Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704 [TBL] [Abstract][Full Text] [Related]
13. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention. Bäuerle T; Saake M; Uder M Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385 [TBL] [Abstract][Full Text] [Related]